{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:53:22Z","timestamp":1785434002740,"version":"3.56.0"},"reference-count":26,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union, European Regional Development Fund"},{"DOI":"10.13039\/501100014181","name":"Junta de Extremadura","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014181","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/01df4mv68","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014181","name":"Ministerio de Hacienda","doi-asserted-by":"publisher","award":["GR24094"],"award-info":[{"award-number":["GR24094"]}],"id":[{"id":"10.13039\/501100014181","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet. Sci.","Veterinary Sciences"],"abstract":"<jats:p>Doxorubicin-induced cardiotoxicity is an important concern in veterinary oncology, and early detection of myocardial injury remains clinically challenging. This exploratory pilot study described changes in cardiac fatty acid-binding protein (h-FABP), cardiac troponin I (cTnI), NT-proBNP, conventional echocardiographic variables, and 24-h Holter-derived heart rate variability parameters in dogs with hemangiosarcoma treated with doxorubicin. Fourteen dogs were prospectively evaluated before treatment initiation and one week after the third doxorubicin dose, corresponding to a cumulative dose of 90 mg\/m2. The study did not include a control group, a predefined cardiotoxicity endpoint, or diagnostic-performance analysis. Plasma biomarkers, echocardiographic parameters, ventricular arrhythmic events, and Holter-derived time- and frequency-domain heart rate variability variables were compared between both time points. Cardiac troponin I increased significantly after three doxorubicin doses, from a median of 0.05 ng\/mL to 0.15 ng\/mL (p = 0.002). In contrast, h-FABP did not change significantly, with median values of 2.43 ng\/mL at baseline and 2.62 ng\/mL after treatment (p = 0.27). NT-proBNP also showed no significant change (p = 0.87). Among echocardiographic variables, E-point septal separation, fractional shortening, ejection fraction, LA\/Ao, and LVDd index did not change significantly. Ventricular arrhythmic events were infrequent and were described descriptively, whereas Holter-derived HRV variables did not show statistically significant differences between time points. In this exploratory cohort, cTnI increased after three doxorubicin doses, whereas h-FABP and NT-proBNP did not change significantly at the evaluated time point. Because h-FABP was measured one week after treatment, its potential short-term post-infusion release cannot be assessed. Larger studies with serial early sampling, predefined cardiotoxicity endpoints, appropriate control groups, and adjusted statistical analyses are required.<\/jats:p>","DOI":"10.3390\/vetsci13080735","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:54:26Z","timestamp":1785153266000},"page":"735","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploratory Evaluation of Cardiac Fatty Acid-Binding Protein (H-FABP), Troponin I, NT-proBNP, Echocardiography, and Holter Monitoring for the Assessment of Doxorubicin-Induced Cardiac Damage in Dogs"],"prefix":"10.3390","volume":"13","author":[{"given":"Paloma","family":"Nicol\u00e1s-Barcel\u00f3","sequence":"first","affiliation":[{"name":"MINVET Research Group, Departamento de Medicina Animal, Facultad de Veterinaria, Universidad de Extremadura, 10003 C\u00e1ceres, Spain"},{"name":"Veterinary Teaching Hospital, Veterinary Faculty, University of Extremadura, 10003 C\u00e1ceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Fortes-D\u00edaz","sequence":"additional","affiliation":[{"name":"Veterinary Teaching Hospital, Veterinary Faculty, University of Extremadura, 10003 C\u00e1ceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3341-7331","authenticated-orcid":false,"given":"Rafael","family":"Barrera","sequence":"additional","affiliation":[{"name":"MINVET Research Group, Departamento de Medicina Animal, Facultad de Veterinaria, Universidad de Extremadura, 10003 C\u00e1ceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1033-2004","authenticated-orcid":false,"given":"Pablo","family":"Cardenal-Morales","sequence":"additional","affiliation":[{"name":"Veterinary Teaching Hospital, Veterinary Faculty, University of Extremadura, 10003 C\u00e1ceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9015-7690","authenticated-orcid":false,"given":"Jos\u00e9 Ignacio","family":"Crist\u00f3bal","sequence":"additional","affiliation":[{"name":"MINVET Research Group, Departamento de Medicina Animal, Facultad de Veterinaria, Universidad de Extremadura, 10003 C\u00e1ceres, Spain"},{"name":"Veterinary Teaching Hospital, Veterinary Faculty, University of Extremadura, 10003 C\u00e1ceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2952-0184","authenticated-orcid":false,"given":"\u00c1ngela","family":"Dur\u00e1n","sequence":"additional","affiliation":[{"name":"MINVET Research Group, Departamento de Medicina Animal, Facultad de Veterinaria, Universidad de Extremadura, 10003 C\u00e1ceres, Spain"},{"name":"Veterinary Teaching Hospital, Veterinary Faculty, University of Extremadura, 10003 C\u00e1ceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Sevidane","sequence":"additional","affiliation":[{"name":"MINVET Research Group, Departamento de Medicina Animal, Facultad de Veterinaria, Universidad de Extremadura, 10003 C\u00e1ceres, Spain"},{"name":"Veterinary Teaching Hospital, Veterinary Faculty, University of Extremadura, 10003 C\u00e1ceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3110-6062","authenticated-orcid":false,"given":"Francisco Javier","family":"Duque","sequence":"additional","affiliation":[{"name":"MINVET Research Group, Departamento de Medicina Animal, Facultad de Veterinaria, Universidad de Extremadura, 10003 C\u00e1ceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: Pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet. Genom."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","article-title":"Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies","volume":"52","author":"Octavia","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/0006-291X(82)91976-3","article-title":"Adriamycin inactivates cytochrome c oxidase by exclusion of the enzyme from its cardiolipin essential environment","volume":"104","author":"Goormaghtigh","year":"1982","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"ref_6","first-page":"460","article-title":"Effect of anthracycline antibiotics on oxygen radical formation in rat heart","volume":"43","author":"Doroshow","year":"1983","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1939-1676.2009.0347.x","article-title":"Association of Plasma N-Terminal Pro-B-Type Natriuretic Peptide Concentration with Mitral Regurgitation Severity and Outcome in Dogs with Asymptomatic Degenerative Mitral Valve Disease","volume":"23","author":"Chetboul","year":"2009","journal-title":"J. Vet. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/01.CIR.58.6.1072","article-title":"Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements","volume":"58","author":"Sahn","year":"1978","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0928-4680(03)00026-9","article-title":"Telemetrically monitored arrhythmogenic effects of doxorubicin in a dog model of heart failure","volume":"9","author":"Vaynblat","year":"2003","journal-title":"Pathophysiology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1590\/S0102-09352006000600010","article-title":"Holter electrocardiography in dogs showing doxorubicin-induced dilated cardiomyopathy","volume":"58","author":"Andrade","year":"2006","journal-title":"Arq. Bras. Med. Vet. Zootec."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jvim.13801","article-title":"Cardiac Troponins in Dogs and Cats","volume":"30","author":"Langhorn","year":"2016","journal-title":"J. Vet. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cll.2015.05.005","article-title":"Using Cardiac Biomarkers in Veterinary Practice","volume":"35","author":"Oyama","year":"2015","journal-title":"Clin. Lab. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/jvim.14586","article-title":"Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial","volume":"30","author":"Boswood","year":"2016","journal-title":"J. Vet. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12944-024-02264-0","article-title":"Heart-type fatty acid binding protein (H-FABP) as an early biomarker in sepsis-induced cardiomyopathy: A prospective observational study","volume":"23","author":"Chang","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0009-9120(91)90571-U","article-title":"Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction","volume":"24","author":"Tanaka","year":"1991","journal-title":"Clin. Biochem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1476-5810.2004.0045n.x","article-title":"Noninvasive monitoring of doxorubicin cardiotoxicity: A pilot study of two dogs","volume":"2","author":"Selting","year":"2004","journal-title":"Vet. Comp. Oncol."},{"key":"ref_17","first-page":"221","article-title":"Serial measurements of cardiac troponin I (cTnI) in dogs treated with doxorubicin","volume":"64","author":"Surachetpong","year":"2016","journal-title":"Jpn. J. Vet. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1200\/JCO.2010.30.3404","article-title":"Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations with Long-Term Echocardiographic Outcomes","volume":"30","author":"Lipshultz","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/MPH.0b013e31826faf44","article-title":"Use of Cardiac Markers for Monitoring of Doxorubixin-induced Cardiotoxicity in Children with Cancer","volume":"34","author":"Pongprot","year":"2012","journal-title":"J. Pediatr. Hematol.\/Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1743-7563.2012.01588.x","article-title":"Serum NT -pro BNP in the early detection of doxorubicin-induced cardiac dysfunction","volume":"9","author":"Kittiwarawut","year":"2013","journal-title":"Asia-Pac. J. Clncl. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bios.2012.12.057","article-title":"Heart type fatty acid binding protein: Structure, function and biosensing applications for early detection of myocardial infarction","volume":"43","author":"Kakoti","year":"2013","journal-title":"Biosens. Bioelectron."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Rezar, R., Jirak, P., Gschwandtner, M., Derler, R., Felder, T.K., Haslinger, M., Kopp, K., Seelmaier, C., Granitz, C., and Hoppe, U.C. (2020). Heart-Type Fatty Acid-Binding Protein (H-FABP) and its Role as a Biomarker in Heart Failure: What Do We Know So Far?. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010164"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e2683","DOI":"10.1002\/vetr.2683","article-title":"Evaluation of heart fatty acid-binding protein as a biomarker for canine leishmaniosis","volume":"192","author":"Fonfara","year":"2023","journal-title":"Vet. Rec."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e70497","DOI":"10.1002\/vms3.70497","article-title":"Impact of Doxorubicin on Cardiac Function in Dogs: Ejection Fraction Changes and Heart Failure Risk","volume":"11","author":"Herrera","year":"2025","journal-title":"Vet. Med. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.56808\/2985-1130.2577","article-title":"Changes in Electrophysiology, Heart Rate Variability and Proteinuria in Clinical Dogs Treated with Doxorubicin Chemotherapy","volume":"44","author":"Buranakarl","year":"2014","journal-title":"Thai J. Vet. Med."}],"container-title":["Veterinary Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-7381\/13\/8\/735\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:13:15Z","timestamp":1785211995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-7381\/13\/8\/735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["vetsci13080735"],"URL":"https:\/\/doi.org\/10.3390\/vetsci13080735","relation":{},"ISSN":["2306-7381"],"issn-type":[{"value":"2306-7381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}